Table 2:
Association between PD-1 Treg/CD8 ratio (measured as continuous variable) and clinical outcomes.
| Treatment Arm | PFS HR (90% CI; p-value) | OS HR (90% CI; p-value) | ORR OR (90% CI; p-value) |
|---|---|---|---|
| Everolimus | 0.93 (0.82–1.05; 0.838) | 0.91 (0.79–1.05; 0.860) | NA |
| Nivolumab | 1.24 (1.04–1.47; 0.023) | 1.22 (1.04–1.449; 0.022) | 0.57 (0.31–1.03; 0.060) |